SARS-Cov-2 Infection in Patients with Inflammatory Bowel Disease: A Single-Center Study SARS-Cov-2 Infection in Inflammatory Bowel Disease
Article Sidebar
Main Article Content
Abstract
Objective: Inflammatory bowel diseases (IBDs) are polygenic disorders. Patients with IBD, especially ulcerative colitis (UC), are more vulnerable to infections because of medications. Key COVID-19-related factors/risks have not been well-researched in IBD patients. In this study, we compared IBD patients with control patients who presented to our clinic with COVID-19 infection suspicion regarding COVID-19 PCR test positivity, COVID-19 pneumonia, hospitalization, and need for treatment at the intensive care unit (ICU).
Material and Methods: Thiscohort study included 480 IBD patients as cases and 9,269 age- and gender-matched control patients who came to our hospital for complaints/checkups and were tested for COVID-19 PCR.
Results: Covid-19 positivity was higher in IBD patients than in controls. COVID-19 pneumonia rates were higher in IBD compared to the pneumonia rate of Turkey — mainly due to the high prevalence of COVID-19 pneumonia in UC as none of the Crohn’s disease (CD) patients experienced COVID-19 pneumonia. Hospitalization was significantly higher in UC than in CD and higher in IBD than in controls. Hospitalization at ICU was significantly higher in UC than in the controls. There were no IBD patients who died because of COVID-19 infection.
Conclusion: IBD patients have a significantly higher rate of COVID-19 PCR positivity, COVID-19 pneumonia, hospitalization, and the need for ICU than the controls; however, mortality is comparable.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2022-04-22
Published 2022-05-17
References
Kelsen JR, Sullivan KE. Inflammatory bowel disease in primary immunodeficiencies. Curr Allergy Asthma Rep. 2017;17(8):57. doi: 10.1007/s11882-017-0724-z DOI: https://doi.org/10.1007/s11882-017-0724-z
Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis. 2007;8(2):65-71. doi: 10.1111/j.1443-9573.2007.00287.x DOI: https://doi.org/10.1111/j.1443-9573.2007.00287.x
Veauthier B, Hornecker JR. Crohn's Disease: Diagnosis and management. Am Fam Physician. 2018;98(11):661-9.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis. Lancet. 2017;389(10080):1756-70. doi: 10.1016/S0140-6736(16)32126-2 DOI: https://doi.org/10.1016/S0140-6736(16)32126-2
Izda V, Jeffries MA, Sawalha AH. COVID-19: A review of therapeutic strategies and vaccine candidates. Clin Immunol. 2021;222:108634. doi: 10.1016/j.clim.2020.108634 DOI: https://doi.org/10.1016/j.clim.2020.108634
MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307(5717):1920-5. doi: 10.1126/science.1106442 DOI: https://doi.org/10.1126/science.1106442
Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti–tumor necrosis factor therapy for pediatric inflammatory bowel disease: A systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443-51. doi: 10.1016/j.cgh.2014.01.021 DOI: https://doi.org/10.1016/j.cgh.2014.01.021
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8. doi: 10.1016/j.cell.2020.02.052 DOI: https://doi.org/10.1016/j.cell.2020.02.052
Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532(1):107-10. doi: 10.1016/S0014-5793(02)03640-2 DOI: https://doi.org/10.1016/S0014-5793(02)03640-2
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-4. doi: 10.1001/jama.2020.3786 DOI: https://doi.org/10.1001/jama.2020.3786
Garg M, Royce SG, Tikellis C, Shallue C, Batu D, Velkoska E, et al. Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: A novel therapeutic target? Gut. 2020;69(5):841-51. doi: 10.1136/gutjnl-2019-318512 DOI: https://doi.org/10.1136/gutjnl-2019-318512
Ning L, Shan G, Sun Z, Zhang F, Xu C, Lou X, et al. Quantitative proteomic analysis reveals the deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in inflammatory bowel disease. Biomed Res Int. 2019;2019:3950628. doi: 10.1155/2019/3950628 DOI: https://doi.org/10.1155/2019/3950628
Jablaoui A, Kriaa A, Mkaouar H, Akermi N, Soussou S, Wysocka M, et al. Fecal serine protease profiling in inflammatory bowel diseases. Front Cell Infect Microbiol. 2020;10:21. doi: 10.3389/fcimb.2020.00021 DOI: https://doi.org/10.3389/fcimb.2020.00021
Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study. Gut. 2020;69(7):1213-7. doi: 10.1136/gutjnl-2020-321411 DOI: https://doi.org/10.1136/gutjnl-2020-321411
Rodríguez-Lago I, Ramírez de la Piscina P, Elorza A, Merino O, Ortiz de Zárate J, Cabriada JL. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain). Gastroenterology. 2020;159(2):781-3. doi: 10.1053/j.gastro.2020.04.043 DOI: https://doi.org/10.1053/j.gastro.2020.04.043
Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52(2):276-83. doi: 10.1111/apt.15804 DOI: https://doi.org/10.1111/apt.15804
Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for COVID-19 infection? J Crohns Colitis. 2020;14(9):1334-6. doi: 10.1093/ecco-jcc/jjaa061 DOI: https://doi.org/10.1093/ecco-jcc/jjaa061